UNSPSC 51293012: Amitriptyline hydrochloride

This classification denotes a tricyclic antidepressant with the molecular formula C20H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26LUD4JO9K, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine but more generally known as amitriptyline hydrochloride, which bears US NIH Compound Identifier 2160. European Medicines Agency schedules Amitriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00474MIG.

UNSPSC 51293012 Amitriptyline hydrochloride (Commodity) shows a mismatch between the code's nominal scope and the recent state and local solicitations tagged under it. The code specifies a single pharmaceutical active ingredient, but the three most recent opportunities span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program implementation (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and over-the-counter products sourced through authorized wholesalers (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target amitriptyline hydrochloride specifically. The actual buying activity reflects state and local health departments, human services agencies, and cooperative purchasing organizations procuring pharmaceutical products and systems at scale—naloxone for opioid response, generic drugs through wholesaler networks, and prescription-fulfillment infrastructure—rather than a single psychiatric medication.

Activity concentrates in Texas, Minnesota, and Florida, with Minnesota's MMCAP representing a multistate cooperative vehicle that includes Oregon. The Seminole County IFB (solicitation IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) explores direct-to-manufacturer prescription contracting capabilities; and the MMCAP RFP (S1070000015802, due March 26, 2026) establishes statewide contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026. The code shows limited relevant recent activity tied to the specific pharmaceutical specified and warrants reassessment against the actual commodity being procured.